Follow-The-Filings

Security · featured owners

NKTR

Nektar Therapeutics COM NEW Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 4.2%
  • $22M
  • 1 add 1 exit

Who owns this now

Largest portfolio weights among featured holders · max 4.2% (Nathan Fischel - Dafna Ca...) · not free-float ownership

  1. Nathan Fischel add 4.2%

holders

sorted by % of portfolio · long equity only · exits show last held size · open a manager for their book

history
Nathan Fischel - Dafna Capital Management 2026 Q2 4.2% Add +92.7% 318,380 $22M hist
Farallon Capital Management exited 2026 Q2 last 2026 Q1 0% Exit 0.00 pp 4,000 $288K hist

1 current · 1 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $90.12M $98.43M $55.23M
Gross profit * $56.35M $67.74M $55.23M
Gross margin * 62.5% 68.8% 100.0%
Net income -$276.06M -$118.96M -$164.08M
Net margin * -306.3% -120.9% -297.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $330.7M $261.29M $266.27M
Total non-current assets * $67.33M $42.56M $14.14M
Total assets $398.03M $303.85M $280.41M
Total current liabilities $51.27M $61.4M $53.54M
Total non-current liabilities * $215.78M $181.71M $137.04M
Total equity $130.99M $60.74M $89.83M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$192.61M -$175.71M -$208.51M
Cash from investing $139.56M $142.57M -$1.2M
Cash from financing $30,000 $42.12M $180.57M
Net change in cash -$52.95M $8.98M -$29.14M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders